Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years

• RA disease onset after 16 years of age and has had the disease for at least 6 months

• Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

Exclusion Criteria:

• Evidence of unstable clinically significant disease